Revisiting the prevention of bone loss at menopause

Menopause

Volumn 19, Issue 11, 2012, Pages 1173-1175

  McClung, Michael R ^a  

^a OREGON OSTEOPOROSIS CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ESTROGEN; GESTAGEN; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; ZOLEDRONIC ACID;

BONE DENSITY; BONE MATRIX; BONE TISSUE; BONE TURNOVER; CLINICAL FEATURE; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN DEFICIENCY; FEMUR NECK; FEMUR NECK FRACTURE; FOLLOW UP; FRACTURE; FRAGILITY FRACTURE; HAZARD RATIO; HIGH RISK POPULATION; HIP FRACTURE; HUMAN; LIFESTYLE; LONG TERM CARE; LUMBAR SPINE; MENOPAUSE; NUTRITIONAL ASSESSMENT; NUTRITIONAL STATUS; OSTEOLYSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SPINE FRACTURE; TREATMENT DURATION;

BONE RESORPTION; FEMALE; FRACTURES, BONE; HUMANS; MENOPAUSE; WOMEN'S HEALTH;

EID: 84868705996     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e318274fb1d     Document Type: Review

References (28)

1. Recker R, Lappe J, Davies K, Heaney R. Characterization of peri-menopausal bone loss: A prospective study. J Bone Miner Res 2000;15: 1965-1973.
2. Zhai G, Hart DJ, Valdes AM, et al. Natural history and risk factors for bone loss in postmenopausal Caucasian women: A 15-year follow-up population-based study. Osteoporos Int 2008;19:1211-1217.
3. Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 2008;93:861-868. (Pubitemid 351398564)
4. Dufresne TE, Chmielewski PA, Manhart MD, et al. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 2003;73:423-432. (Pubitemid 37466634)
5. Hosking DJ, Ross PD, Thompson DE, et al. Evidence that increased calcium intake does not prevent early postmenopausal bone loss. Clin Ther 1998;20:933-944. (Pubitemid 28535729)
6. Cooper L, Clifton-Bligh PB, Nery ML, et al. Vitamin D supplementation and bone mineral density in early postmenopausal women. Am J Clin Nutr 2003;77:1324-1329. (Pubitemid 44858453)
7. Puntila E, Kröger H, Lakka T, et al. Leisure-time physical activity and rate of bone loss among peri-and postmenopausal women: A longitudinal study. Bone 2001;29:442-446. (Pubitemid 33026465)
8. National Osteoporosis Foundation. Clinician's guide to the prevention and treatment of osteoporosis. Available at: http://www.nof.org/sites/default/ files/pdfs/NOF-ClinicianGuide2009-v7.pdf Accessed September 14, 2012.
9. Scientific Advisory Council of Osteoporosis Canada. Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2010;182:1864-1873.
10. Cauley JA, Danielson ME, Greendale GA, et al. Bone resorption and fracture across the menopausal transition: the Study of Women's Health Across the Nation. Menopause 2012;19:1200-1207.
11. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333. (Pubitemid 34761611)
12. Hannon R, Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 2000;11(Suppl 6):S30-S44. (Pubitemid 32039511)
13. Prieto-Alhambra D, Premaor MO, Fina Avilés F, et al. The association between fracture and obesity is site-dependent: A population-based study in postmenopausal women. J Bone Miner Res 2012;27:294-300.
14. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: An observational study. Lancet 1999;353:878-882. (Pubitemid 29126875)
15. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280: 2077-2082. (Pubitemid 29014065)
16. Mosekilde L, Beck-Nielsen H, SLrensen OH, et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal womenVresults of the Danish Osteoporosis Prevention Study. Maturitas 2000;36:181-193.
17. Hundrup YA, HLidrup S, Ekholm O, et al. Risk of low-energy hip, wrist, and upper arm fractures among current and previous users of hormone replacement therapy: the Danish Nurse Cohort Study. Eur J Epidemiol 2004;19:1089-1095. (Pubitemid 40228497)
18. Dell RM, Adams AL, Greene DF, et al. Incidence of atypical non-traumatic diaphyseal fractures of the femur [published online ahead of print July 26, 2012]. J Bone Miner Res. doi: 10.1002/jbmr.1719.
19. The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996;276:1389-1396.
20. Greendale GA, Espeland M, Slone S, et al. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. Arch Intern Med 2002;162:665-672. (Pubitemid 34226393)
21. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endome-trium in postmenopausal women. N Engl J Med 1997;337:1641-1647. (Pubitemid 27510100)
22. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endo-crinol Metab 2011;96:972-980.
23. Ravn P, Weiss SR, Rodriguez-Portales JA, et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab 2000;85:1492-1497. (Pubitemid 32289491)
24. Wasnich RD, Bagger YZ, Hosking DJ, et al. Early Postmenopausal Intervention Cohort Study Group. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 2004;11;622-630. (Pubitemid 40353225)
25. McClung M, Miller P, Recknor C, et al. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: A randomized controlled trial. Obstet Gynecol 2009;114:999-1007.
26. Grey A, Bolland M, Wattie D, et al. Prolonged antiresorptive activity of zoledronate: A randomized, controlled trial. J Bone Miner Res 2010;25: 2251-2555.
27. Grey A, Bolland M, Wong S, et al. Low-dose zoledronate in osteopenic postmenopausal women: A randomized controlled trial. J Clin Endocrinol Metab 2012;97:286-292.
28. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012;27: 243-254.